Skip to main content
Explore URMC

menu

Ovarian Cancer: A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Research Question:
Can niraparib help delay worsening of cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug?

Basic Study Information

Purpose:
If you agree to be in this study, you will either take the Study Drug, niraparib, capsules or placebo capsules by mouth once daily. You have a 2 in 3 chance of receiving study drug. Neither you or your study doctor will know if you receive niraparib or placebo.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/study/NCT02655016?term=tesaro+PRIMA&rank=1&show_locs=Y#locn
Study Reference #: IGYO17056

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search